Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 208.85
(3.37%)
INR 208.85
(3.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.38 Billion INR | -2651.25% |
| 2022 | -50.52 Million INR | 77.57% |
| 2021 | -225.26 Million INR | 56.81% |
| 2020 | -521.55 Million INR | -57.42% |
| 2019 | -331.31 Million INR | 4.65% |
| 2018 | -347.49 Million INR | -459.4% |
| 2017 | -62.11 Million INR | 48.79% |
| 2016 | -121.31 Million INR | -152.84% |
| 2015 | 229.59 Million INR | -5.5% |
| 2014 | 242.94 Million INR | 4.03% |
| 2013 | 233.53 Million INR | 1.26% |
| 2012 | 230.63 Million INR | -7.79% |
| 2011 | 250.12 Million INR | 17.61% |
| 2010 | 212.68 Million INR | 45.23% |
| 2009 | 146.44 Million INR | -29.9% |
| 2008 | 208.9 Million INR | -38.73% |
| 2007 | 340.93 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2024 Q2 | -168.25 Million INR | 0.0% |
| 2023 Q2 | 1.27 Million INR | -99.89% |
| 2023 Q3 | 1.11 Billion INR | 87770.87% |
| 2023 Q4 | -1.38 Billion INR | -224.55% |
| 2023 Q1 | 1.14 Billion INR | 2368.93% |
| 2023 FY | -1.38 Billion INR | -2651.25% |
| 2022 FY | -50.52 Million INR | 77.57% |
| 2022 Q4 | -50.52 Million INR | -110.57% |
| 2022 Q3 | 478.11 Million INR | 394.25% |
| 2022 Q1 | 482.94 Million INR | 314.4% |
| 2022 Q2 | -162.48 Million INR | -133.65% |
| 2021 Q1 | 602.29 Million INR | 215.48% |
| 2021 FY | -225.26 Million INR | 56.81% |
| 2021 Q4 | -225.26 Million INR | -142.03% |
| 2021 Q3 | 536 Million INR | 234.99% |
| 2021 Q2 | -397.05 Million INR | -165.92% |
| 2020 FY | -521.55 Million INR | -57.42% |
| 2020 Q3 | 577 Million INR | 217.02% |
| 2020 Q2 | -493.08 Million INR | 0.0% |
| 2020 Q4 | -521.55 Million INR | -190.39% |
| 2019 Q2 | 39.74 Million INR | -89.69% |
| 2019 Q1 | 385.34 Million INR | 210.89% |
| 2019 Q3 | 447.68 Million INR | 1026.51% |
| 2019 FY | -331.31 Million INR | 4.65% |
| 2019 Q4 | -331.31 Million INR | -174.01% |
| 2018 FY | -347.49 Million INR | -459.4% |
| 2018 Q4 | -347.49 Million INR | -220.96% |
| 2018 Q3 | 287.27 Million INR | 442.24% |
| 2018 Q2 | 52.98 Million INR | -63.49% |
| 2018 Q1 | 145.12 Million INR | 333.62% |
| 2017 FY | -62.11 Million INR | 48.79% |
| 2017 Q1 | 200.59 Million INR | 265.35% |
| 2017 Q2 | -94.16 Million INR | -146.94% |
| 2017 Q4 | -62.11 Million INR | 0.0% |
| 2016 Q3 | 134.01 Million INR | 906.32% |
| 2016 FY | -121.31 Million INR | -152.84% |
| 2016 Q4 | -121.31 Million INR | -190.52% |
| 2016 Q2 | 13.31 Million INR | -91.43% |
| 2016 Q1 | 155.33 Million INR | -32.34% |
| 2015 Q1 | 150.16 Million INR | -38.19% |
| 2015 Q2 | 239.95 Million INR | 59.8% |
| 2015 Q4 | 229.59 Million INR | 59.25% |
| 2015 Q3 | 144.16 Million INR | -39.92% |
| 2015 FY | 229.59 Million INR | -5.5% |
| 2014 Q2 | 232.86 Million INR | 84.75% |
| 2014 FY | 242.94 Million INR | 4.03% |
| 2014 Q4 | 242.94 Million INR | 92.04% |
| 2014 Q3 | 126.5 Million INR | -45.67% |
| 2014 Q1 | 126.04 Million INR | -46.03% |
| 2013 FY | 233.53 Million INR | 1.26% |
| 2013 Q1 | 103.43 Million INR | -55.15% |
| 2013 Q3 | 91.31 Million INR | -62.51% |
| 2013 Q2 | 243.56 Million INR | 135.47% |
| 2013 Q4 | 233.53 Million INR | 155.75% |
| 2012 FY | 230.63 Million INR | -7.79% |
| 2012 Q4 | 230.63 Million INR | 0.0% |
| 2012 Q2 | 260.85 Million INR | 0.0% |
| 2011 Q4 | 250.12 Million INR | 0.0% |
| 2011 Q2 | - INR | 0.0% |
| 2011 FY | 250.12 Million INR | 17.61% |
| 2010 FY | 212.68 Million INR | 45.23% |
| 2009 FY | 146.44 Million INR | -29.9% |
| 2008 FY | 208.9 Million INR | -38.73% |
| 2007 FY | 340.93 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 135.954% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 137.634% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 51.105% |
| Granules India Limited | 9.28 Billion INR | 114.967% |
| Indoco Remedies Limited | 6.47 Billion INR | 121.462% |
| Achyut Healthcare Limited | -3.74 Million INR | -37004.378% |
| Ajanta Pharma Limited | -954.9 Million INR | -45.558% |
| Alkem Laboratories Limited | -1.6 Billion INR | 13.637% |
| Alpa Laboratories Limited | 35.36 Million INR | 4030.464% |
| Brooks Laboratories Limited | 49.48 Million INR | 2908.791% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 72.27% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 142.132% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -20.054% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 110.764% |
| Eris Lifesciences Limited | 13.8 Billion INR | 110.067% |
| FDC Limited | -57.75 Million INR | -2306.722% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 67.565% |
| Gufic Biosciences Limited | 3.19 Billion INR | 143.513% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 66.532% |
| Ipca Laboratories Limited | 11.41 Billion INR | 112.176% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 171.908% |
| Lasa Supergenerics Limited | 205.79 Million INR | 775.382% |
| Laurus Labs Limited | 24.38 Billion INR | 105.7% |
| Lupin Limited | 17.19 Billion INR | 108.085% |
| Mankind Pharma Limited | -9.9 Billion INR | 85.972% |
| Medicamen Biotech Limited | 160.31 Million INR | 966.994% |
| Medico Remedies Limited | 78.67 Million INR | 1866.628% |
| Megasoft Limited | 1.28 Billion INR | 208.119% |
| NATCO Pharma Limited | -5.81 Billion INR | 76.106% |
| Piramal Pharma Limited | 42.27 Billion INR | 103.288% |
| RPG Life Sciences Limited | -364.7 Million INR | -281.116% |
| Sigachi Industries Limited | 859.94 Million INR | 261.629% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 98.082% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 1058.731% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 3107.79% |
| Unichem Laboratories Limited | 931.91 Million INR | 249.148% |
| Wanbury Limited | 1.1 Billion INR | 225.686% |
| Windlas Biotech Limited | -273.04 Million INR | -409.057% |
| ZIM Laboratories Limited | 983.6 Million INR | 241.31% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 135.53% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -47.582% |
| Divi's Laboratories Limited | -39.77 Billion INR | 96.505% |
| Hester Biosciences Limited | 2.29 Billion INR | 160.676% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 40.804% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -458.672% |
| Bal Pharma Limited | 1.26 Billion INR | 210.001% |
| Strides Pharma Science Limited | 23.25 Billion INR | 105.976% |
| Venus Remedies Limited | -267.7 Million INR | -419.212% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 153.215% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 122.574% |
| Shilpa Medicare Limited | 9.06 Billion INR | 115.325% |
| Aarti Drugs Limited | 5.54 Billion INR | 125.051% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -26.208% |
| Suven Life Sciences Limited | -1.63 Billion INR | 14.869% |
| Ind-Swift Limited | 9.5 Billion INR | 114.618% |
| Valiant Laboratories Limited | -295.03 Million INR | -371.112% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 149.267% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 113.859% |
| Themis Medicare Limited | 764.96 Million INR | 281.699% |
| Hikal Limited | 7.96 Billion INR | 117.446% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 104.367% |
| Sequent Scientific Limited | 4.17 Billion INR | 133.263% |
| Novartis India Limited | -5.89 Billion INR | 76.406% |
| Wockhardt Limited | 18.27 Billion INR | 107.608% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 105.134% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -7435.13% |
| Neuland Laboratories Limited | -214.05 Million INR | -549.324% |
| Morepen Laboratories Limited | -231.17 Million INR | -501.248% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 1257.899% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 242.438% |